Contrast-induced encephalopathy presenting with refractory status epilepticus following endovascular coiling of an intracranial aneurysm: A case report and literature review Authors: Long Jing, Zexian Zhao, Shu Wan, Ming Wang, Guorui Shao Published: 2026 ABSTRACT AbstractAcute symptomatic seizures as the main manifestation of contrast-induced encephalopathy are relatively uncommon. A 50-year-old woman was admitted to our hospital with an unruptured right middle cerebral artery bifurcation aneurysm and underwent elective endovascular stent-assisted coiling. The interventional procedure was uneventful; however, she developed generalized tonic–clonic seizures consistent with status epilepticus on the first postoperative day. A computed tomography scan obtained on postoperative day 1 revealed mild edema in the right cerebral hemisphere, suggestive of contrast-induced encephalopathy. Following prompt antiepileptic therapy and supportive care, the patient achieved complete neurological recovery without residual deficits. By reporting this case and reviewing relevant literature, we summarize the clinical characteristics of contrast-induced encephalopathy presenting primarily with seizures, thereby providing clinical evidence to assist clinicians in the early diagnosis and optimal management of this condition.Keywords: Contrast-induced encephalopathy, seizure, intracranial aneurysm, cerebral angiography, case report Introduction Contrast-induced encephalopathy (CIE) is an uncommon complication associated with the administration of iodine-based contrast agents during angiographic procedures. 1 The clinical manifestations of CIE are heterogeneous, ranging from mild neurological deficits, including motor weakness and sensory disturbances, to severe presentations such as seizures, visual disturbances, aphasia, and loss of consciousness.2,3 Most CIE-related symptoms are transient and resolve spontaneously within 24–48 h; however, in rare cases, symptoms may persist for up to 2 weeks. 4 Transient cortical blindness is the most common clinical manifestation of CIE, 5 although severe prolonged neurological deficits have also been reported. 6 Seizures are a recognized but infrequent manifestation of CIE. According to previous reviews, the incidence of seizures among all CIE cases is 14.2%, with a potentially higher incidence following cerebral angiography than following coronary angiography. 7 Herein, we present a case of probable CIE characterized by refractory status epilepticus (SE) on the second postoperative day after endovascular coiling of an unruptured intracranial aneurysm. Notably, the initial computed tomography (CT) scans revealed no specific abnormalities, highlighting the need for clinical vigilance in recognizing this complication despite its generally favorable prognosis. This case report, together with a literature review, aims to enhance understanding of the clinical variability and management of CIE presenting with SE. Case presentation A 50-year-old woman was admitted to our institution for treatment of an unruptured right middle cerebral artery (MCA) bifurcation aneurysm. Physical examination on admission was unremarkable. She had a medical history of hypertension, which was well controlled with oral amlodipine. No other vascular risk factors, such as smoking, alcohol consumption, diabetes mellitus, dyslipidemia, family history of cardiovascular disease, or obesity, were identified. Computed tomography angiography (CTA) revealed a right MCA aneurysm (Figure 1(a)). The patient underwent uneventful endovascular stent-assisted coiling, with a total procedural duration of 110 min and administration of 120 mL of iodine contrast agent. On the evening after the operation, the patient developed a headache and nausea and vomited twice. Limb muscle strength was normal at that time. Emergency postoperative emergency CT scans (Figure 1(b) and (c)) showed no signs of intracerebral hemorrhage, subarachnoid hemorrhage, or focal hypodensity suggestive of ischemia. After symptomatic treatment with celecoxib, the headache was slightly relieved. As the patient presented with no severe neurological deficits, her symptoms improved after symptomatic treatment, and cranial CT showed no abnormal findings, CIE was not considered a primary diagnosis at that time, although the condition might already have developed. (a) Three-dimensional volume rendering of CTA showing a right MCA bifurcation aneurysm. (b–i) Postoperative day 0 CT showing no signs of intracerebral hemorrhage, subarachnoid hemorrhage, or focal hypodensity suggestive of ischemia. CTA: computed tomography angiography; MCA: middle cerebral artery; CT: computed tomography. On postoperative day 1, the patient presented with left limb weakness of grade II according to the Manual Muscle Test and a high fever, with a peak temperature of 39.3°C. Routine blood tests revealed a mild increase in white blood cell count, while C-reactive protein (CRP) levels were within the normal range. No significant abnormalities were found in electrolyte levels or liver or renal function. The patient’s blood pressure remained stable throughout the postoperative period, with no hypertensive episodes. Repeat CTA confirmed patency of the right MCA (Figure 2(a)) and revealed mild edema in the right cerebral hemisphere (Figure 2(b)). The fever and leukocytosis resolved spontaneously without antibiotic treatment. Based on the clinical presentation, imaging findings, and temporal association with contrast administration, a diagnosis of CIE was considered. Treatment with mannitol (125 mL intravenously every 12 h) was initiated to reduce intracranial pressure, together with butylphthalide (25 mg intravenously twice daily) to improve cerebral microcirculation. (a) Postoperative day 1 CTA showing the patency of the right MCA. (b) Postoperative day 1 CT showing mild edema in the right cerebral hemisphere. (c) Postoperative day 1 bedside EEG demonstrating high-amplitude spike-and-wave complexes, confirming status epilepticus. (d) Postoperative day 4 EEG showing no significant abnormal electrical activity. (e) Six-month follow-up EEG demonstrating normal electrical activity. (f, g) Six-month follow-up brain CT scans showing no residual hemorrhage, ischemia, or edema. CTA: computed tomography angiography; MCA: middle cerebral artery; CT: computed tomography; EEG: electroencephalogram. At 10:30 on postoperative day 1, the patient developed SE. Immediate intravenous administration of diazepam (10 mg) failed to control the seizure activity and was followed by intravenous sodium valproate (800 mg over 30 min). However, the seizures persisted. Due to persistent refractory SE, the patient was transferred to the intensive care unit for sedation with propofol (2 mg/kg intravenously, followed by continuous infusion at 1 mg/kg/h for 12 h). Emergency bedside electroencephalogram (EEG) confirmed ongoing seizure activity (Figure 2(c)). Following 48 h of sedation and dual antiepileptic therapy (sodium valproate 800 mg intravenously daily and levetiracetam 500 mg intravenously twice daily), the patient’s condition stabilized with no recurrent seizures. Complete discontinuation of sedative agents was associated with full recovery of consciousness and limb muscle strength. Repeat EEG showed no significant abnormal electrical activity (Figure 2(d)). The patient was discharged on oral sodium valproate (500 mg once daily) for 6 months of maintenance therapy. At the 6-month follow-up, the patient remained seizure free. Follow-up EEG (Figure 2(e)) and brain CT showed no residual edema, hemorrhage, or ischemia (Figure 2(f) and (g)). Discussion CIE is a rare and reversible neurotoxic complication of iodine-based contrast agent administration, with a favorable prognosis in most cases, as symptoms typically resolve within 24–48 h. 8 The clinical manifestations of CIE range from mild symptoms, such as headache and vomiting, to severe neurological impairments, with transient cortical blindness being the most common presentation. 5 According to the more recently published diagnostic criteria for CIE, the diagnosis is confirmed by the onset of neurological symptoms within 24 h of contrast administration, with exclusion of vascular occlusion/ischemia, intracranial hemorrhage, pre-existing seizure disorder, biochemical derangement, intracranial malignancy, and recent head trauma. 9 A comprehensive literature review was performed to identify cases of CIE with seizure as the primary clinical manifestation. The search was conducted in PubMed, Embase, and Web of Science databases from January 2000 to December 2024, using the keywords “contrast-induced encephalopathy,” “CIE,” “seizure,” “convulsion,” “angiography,” and “endovascular intervention.” Inclusion criteria were as follows: (a) patients diagnosed with CIE; (b) seizure as the main clinical manifestation; and (c) availability of detailed clinical, imaging, and follow-up data. Exclusion criteria were as follows: (a) cases with incomplete clinical data; (b) cases in which seizures were attributed to other etiologies (e.g. ischemia, infection, or metabolic disturbances); and (c) reviews, meta-analyses, or non-English articles. A total of 28 eligible cases were identified (including our case), which were analyzed for clinical characteristics, risk factors, imaging findings, and treatment outcomes (Table 1).10–29 Table 1.Reported cases of contrast agent-induced encephalopathy with seizure as the main clinical manifestation.Table 1a. Demographic characteristics, surgical procedures, risk factors, and contrast agent-related information of patients. ReferencesSexAgeProcedureRisk factorsContrast mediumContrast medium classVolume (mL) Spina et al. 10 F44 yearsPCIEnd-stage kidney diseaseHTDMIohexolNon-ionic low osmolar190F69 yearsPCICKDDMPrevious contrast reactionIodixanolNon-ionic iso-osmolar320F73 yearsPCIHTDiatrozoateIonic high osmolar800M49 yearsCAGCKDHTDiatrizoateIonic high osmolar610Gonzalez-Pardo et al. 11 F2 monthsCCNRIopromideNon-ionic low-osmolar15Zhang et al. 12 MOver 50 yearsDSAHTDMHyperlipidemiaNRNRNRZhao et al. 13 F50 yearsDSANRIopromideNon-ionic low-osmolar6Kamimura et al. 14 F70 yearsDSANRIopamidolNon-ionic low osmolar43Kahyaoglu et al. 15 M66 yearsLower extremity angiographyNRIohexolNon-ionic low osmolar250Nakao et al. 16 F68 yearsSACHTiopamidolNon-ionic low-osmolar260F66 yearsCoilingNRIomeprolNon-ionic low-osmolar80Liu et al. 17 F84 yearsCAGHTParoxysmal atrial fibrillationChronic bronchitisIopromideNon-ionic low osmolar20F57 yearsPCICKDHTDMIodixanolNon-ionic iso-osmolar130Willman et al. 18 M60 yearsCAGHTDMHypercholesterolemiaIomeronNon-ionic low-osmolar220Zhu et al. 19 M54 yearsCAANRNRNR200Ren et al. 20 F74 yearsCoilingNRIoversolNon-ionic iso-osmolar240Zhang et al. 21 F62 yearsCoilingHTIodixanolNon-ionic iso-osmolar400Table 1a. Demographic characteristics, surgical procedures, risk factors, and contrast agent-related information of patients. ReferencesSexAgeProcedureRisk factorsContrast mediumContrast medium classVolume (mL) Park et al. 22 F58 yearsDSAHT, Hypothyroidism,Peripheral artery occlusive diseaseDepressive disorderIodixanolNon-ionic iso-osmolar220Sansone et al. 23 F6 yearsCCHTAortic isthmic coarctationIodateNon-ionic high-osmolar500Donepudi et al. 24 F73 yearsAAGHTHyperlipidemiaCKDMyocardial infarctionIodixanolNon-ioniciso-osmolar248Leong et al. 25 F59 yearsAAGRenal impairmentHTDiatrizoateIonic high osmolar150F53 yearsCarotid artery angiographyNRDiatrizoateIonic high osmolar60F70 yearsCAGHTNRIonic1500F72 yearsAAG+CAG+Carotid arteries angiographyRenal impairmentDiatrizoate meglumine;Iothalamate meglumineIonic high osmolar200Yang et al. 26 M51 yearsCAAHTDM coronary artery diseaseIohexolNon-ionic iso-osmolar<50Lei et al. 27 M76 yearsCAGHTDMTransient ischemic attacksIodixanolNon-ionic iso-osmolar150Frye et al. 28 M18 monthsCCNRIoversollow-osmolar nonionicNRPašara et al. 29 M75 yearsCAGHeart transplantCKDIodateNon-ionic low-osmolar140Our caseF50 yearsSACHTIodixanolNon-ionic iso-osmolar120Table 1b. Clinical manifestations, seizure classification, imaging findings, onset time, symptom duration, treatment regimens, and prognosis of patients.ReferencesPresentationClassification of seizure typeNeuroimagingEpileptic seizureSymptom durationControl epilepsyDuration of epilepsyComplete resolutionSpina et al. 10 Left-sided weakness seizure activityNRCT: contrast enhancement of right cerebral hemisphere4 h after the procedure72 hLorazepamLevetiracetamHemodialysisNRYesPartial seizureHomonymous hemianopiaHemisensory lossHemiparesisFocal motor seizure secondary to generalized tonic–clonic seizureCT: cerebral edema12 h after the procedure24 hLorazepamNRYesMyoclonus, seizure with respiratory arrest, slurred speech, gait instabilityNRCT: contrast enhancement of right frontoparietal lobe EEG diffuse slowingNR24 hNRNRYesSeizuresEncephalopathyNRCT: contrast enhancement of left frontal gyriNR4 hNRNRYesGonzalez-Pardo et al. 11 Clonic movements of the left upper limbPersistent sucking movementsSeizureFocal onset motor seizure (clonic + automatisms)CT: slight diffuse increase in the density of predominantly frontal, parietal, and occipital cortices in the right cerebral hemisphere12 h after the procedure11 daysNRNRYesZhang et al. 12 Slurred speechRight limb weaknessUnconsciousness High fever (39.5°C)Focal onset seizure with impaired consciousnessCT: swelling of the left frontal, temporal, parietal, and occipital lobe brain tissue and higher density of the left cerebral hemisphere than the right cerebral hemisphere7 h after the DSA6 daysDiazepam 10 mgSodium valproate 1.2 gNRYesZhao et al. 13 Fever (38.5°C) Disturbance of consciousnessFrequent blinkingStiffness in the extremitiesFocal onset seizure with impaired awareness, motor seizure (tonic–clonic)CT: no obvious abnormalityMRI: no obvious abnormalityImmediately after angiography10 daysIntravenous rehydrationMannitol dehydrationOther supportive treatmentNRYesKamimura et al. 14 Tonic–clonic seizuresFocal onset seizure with impaired awareness progressing to tonic–clonic seizureCT: high-density signaling in the cortexMRI: high signal intensity in temporal lobe3 h after angiography1 daysLevetiracetamMethylprednisolone pulse therapyNRYesTable 1b. Clinical manifestations, seizure classification, imaging findings, onset time, symptom duration, treatment regimens, and prognosis of patients.ReferencesPresentationClassification of seizure typeNeuroimagingEpileptic seizureSymptom durationControl epilepsyDuration of epilepsyComplete resolutionKahyaoglu et al. 15 ConfusionCortical blindnessFocal onset seizure with impaired consciousnessCT: normal1 h after the procedure24 hHydrationSedative medicationNRYesNakao et al. 16 Decreased vision in both eyesDrowsinessGeneralized convulsionsNRCT: subarachnoid contrast enhancement in bilateral occipital lobe sulci with loss of gray–white differentiation and sulcal effacement1 day after the procedure6 daysLevetiracetam 1 g/dayPhenobarbital 750 mg/dayMethylprednisolone 500 mg/dayNRYesRight hemiparesis, aphasia, altered sensoriumNRNRNR12 monthsNRNRYesLiu et al. 17 Tonic–clonic seizuresGeneralized tonic–clonic seizureCT: high-density regions in the subarachnoid spaceFirst: 10 min after transfer to the CCUSecond: 18 h post CAG2 monthsFirst: sodium valproate 60 mg per hourMannitol 125 mL every 6 hNimodipine 10 mg once a daySecond: 10 mg of dexamethasone once per day for 2 days2–3 minYesTonic–clonic seizuresGeneralized tonic–clonic seizureCT: right parenchymal edemaApproximately 1 day after the procedure72 hAntiepileptic medicationHemodialysisNRYesWillman et al. 18 AphasiaTonic–clonic seizureGeneralized tonic–clonic seizureCT: a large area of parenchymal edema, sulcal effacement, and variable subarachnoid hyperdensity in the right hemisphereOn the morning of the day after the procedure2 monthsNRNRYesZhu et al. 19 Flexion and spasticity in the right armTonic–clonic seizuresGeneralized tonic-clonic seizureMRI: brain edema and high signal in the meningesHalf an hour later after the procedure22 daysContinuous intravenous infusion of midazolam for 48 hLevetiracetamLasting from 10 s to several minutesYesTable 1b. Clinical manifestations, seizure classification, imaging findings, onset time, symptom duration, treatment regimens, and prognosis of patients.ReferencesPresentationClassification of seizure typeNeuroimagingEpileptic seizureSymptom durationControl epilepsyDuration of epilepsyComplete resolutionRen et al. 20 Headaches Slurred speechLeft-hand muscle strength loss dysphoriaTongue deviationTonic–clonic seizuresGeneralized tonic–clonic seizureCT: edema within the right cerebral hemisphere involving the parietal and temporal lobes without hemorrhage3 days after the procedure6 daysDiazepam 10 mgSodium valproate 0.5 g MidazolamDehydration therapyNRYesZhang et al. 21 UnconsciousnessBlindnessHemiplegiaOphthalmoplegiaFeverGeneralized tonic–clonic seizureCT: widespread edema in the right cerebral hemisphereOn the following day after the procedure3 daysMethylprednisolone pulse 80 mg/dayDiazepam 10 mg/dayNRYesPark et al. 22 Tonic–clonic seizureGeneralized tonic–clonic seizureCT: sulcal obliteration of right cerebral hemisphereMRI: gyral swelling and hyperintensity in the right cerebral hemisphereA few hours after the procedure6 daysHydrationIntravenous dexamethasone, mannitol, and anticonvulsantA few secondsYesSansone et al. 23 Tonic–clonic seizureGeneralized tonic–clonic seizureCT: cerebral sulci were of increased densityFirst: 5 min after extubation Second: 2 h later10 daysDiazepamPhenobarbitalPhenytoinDexamethasoneNRYesDonepudi et al. 24 A focal motor seizure in her left leg, arm, and faceFocal motor seizure (clonic) with impaired consciousnessCT: increased hyperdensity and enhancement of right cortexAn hour after ICU admission7 daysLorazepam 4 mgPropofolLevetiracetam 1000 mg twice dailyLasting about 20 minYesTable 1b. Clinical manifestations, seizure classification, imaging findings, onset time, symptom duration, treatment regimens, and prognosis of patients.ReferencesPresentationClassification of seizure typeNeuroimagingEpileptic seizureSymptom durationControl epilepsyDuration of epilepsyComplete resolutionLeong et al. 25 Cortical blindnessHeadacheMyoclonusFocal seizuresCT: bilateral parieto-occipital contrast enhancement2 h after the procedure3 daysDiazepam intramuscular injectionIntravenous injection of phenytoin sodiumDiuresisNRYesPartial motor seizurePartial motor seizureCT: right temporo-parietal contrast enhancementSoon after the last injection24 hDiphenylhydantoin 250 mgDiazepam 10 mgHydrocortisone Sodium succinate100 mg5 minYesSeizureFocal aware motor seizureCT: hyperdensity of right frontalNR24 hNRNRYesPartial motor seizurePartial motor seizureCT: scattered high-density areas in the parietal–frontal lobes of both cerebral hemispheresImmediately after the injection of the contrast agent24 hDiazepamDiphenylhydantoin2 minYesYang et al. 26 Gaze to the rightImpaired consciousness (GCS 7)Tonic–clonic seizureUnconsciousnessGeneralized tonic–clonic seizureCT: left frontal, temporal, and parietal lobes showed low-density shadows and brain sulci and gyri become shallowDuring the procedures7 daysDiazepam 20 mgMidazolamNRdeathLei et al. 27 Slight tremor in the upper limbsSeizuresFocal aware motor seizure (clonic)NR2 hours after the procedure6 hNR2 secondsYesFrye et al. 28 Left arm and leg clonic movementsLethargyIrritabilitySeizureFocal motor seizure with impaired consciousness (clonic)CT: right holohemispheric parenchymal and subarachnoid hyperdensityApproximately 12 h after the procedure6 daysLorazepamPhenobarbitalLess than 3 minYesPašara et al. 29 Unresponsive, head and gaze deviated to the left, with oroalimentary and gestural automatismsFocal motor seizure with impaired consciousness (clonic)CT: no obvious abnormality2 h after the procedure24 hLevetiracetamNRYesOur caseStiffness of limbs, loss of consciousnessElevated lactic acid (9.15 mmol/L)Tonic–clonic seizureTonic–clonic seizureCT: right parenchymal edema2 days after the procedure24 hDiazepamSodium valproateMethylprednisolone20–30 sYesPCI: percutaneous coronary intervention; CAG: coronary angiography; DSA: digital subtraction angiography; SAC: stent-assisted coiling; CC: cardiac catheterization; CAA: carotid artery angioplasty; AAG: aortic arch angiography; HT: hypertension; DM: diabetes mellitus; CT: computed tomography; MRI: magnetic resonance imaging; EEG: electroencephalography; NR: not reported. Reported cases of contrast agent-induced encephalopathy with seizure as the main clinical manifestation. PCI: percutaneous coronary intervention; CAG: coronary angiography; DSA: digital subtraction angiography; SAC: stent-assisted coiling; CC: cardiac catheterization; CAA: carotid artery angioplasty; AAG: aortic arch angiography; HT: hypertension; DM: diabetes mellitus; CT: computed tomography; MRI: magnetic resonance imaging; EEG: electroencephalography; NR: not reported. Analysis of the 29 reviewed cases revealed a female predominance, with 72.4% of cases occurring in women (9 men and 21 women, including our case). The median age was 59 years, and almost all patients were aged over 50 years. Reported risk factors included chronic hypertension (16 cases, 53.3%), diabetes mellitus (7 cases, 23.3%), and renal insufficiency (6 cases, 20.0%). Hypertension and diabetes are known to induce cerebral microvascular injury, increasing blood–brain barrier (BBB) permeability and predisposing patients to CIE.30,31 Renal insufficiency prolongs contrast agent excretion, thereby increasing systemic neurotoxicity and the risk of CIE. No definitive correlation was identified between contrast agent type or dose and the occurrence of CIE. Non-ionic iodine contrast agents are widely used in angiography due to their lower neurotoxicity and reduced vascular endothelial injury. However, our literature review demonstrated that CIE can occur with low-, medium-, or high-osmolar non-ionic iodine contrast agents.11,14,17,25,28 Although high contrast doses may increase neurotoxicity risk, CIE has also been reported with normal or even extremely low contrast doses (6 mL), 12 consistent with the present case, which involved a standard clinical dose range. CIE presenting with seizure exhibits diverse clinical phenotypes, including generalized and focal seizures. Approximately one-third of patients, including our case, present with tonic–clonic seizures. Cerebral CT may demonstrate hemispheric or lobar edema, with ipsilesional contrast enhancement in some cases.10–12,16–18,20,24,25 However, CT findings may be unremarkable in a subset of CIE cases,13,15 as observed in our patient, in whom only mild right hemispheric edema was noted on postoperative day 1 CT, with no significant abnormalities on subsequent scans. Therefore, CIE should still be considered in patients who present with seizures after cerebrovascular interventional therapy, even in the absence of abnormalities on CT or magnetic resonance imaging (MRI). 32 Peri-procedural ischemia was excluded based on postoperative CT findings (no focal hypodensity), CTA results (patent right MCA), and complete resolution of limb weakness without residual deficits. Infection was excluded based on normal CRP levels, absence of meningeal irritation or other infectious signs, and spontaneous resolution of fever and leukocytosis without antibiotic therapy. Hyperperfusion syndrome was excluded based on stable postoperative blood pressure and nonterritorial mild cerebral edema. Posterior reversible encephalopathy syndrome (PRES) was excluded due to the absence of bilateral parieto-occipital edema and no history of renal insufficiency or immunosuppression. Metabolic disturbances were excluded based on normal postoperative electrolyte levels and normal liver and renal function. The core treatment principles for CIE include the following: (a) prompt control of acute symptoms, especially seizures; (b) enhancement of contrast agent excretion; (c) protection of the BBB; and (d) supportive care to prevent complications. Antiepileptic therapy is critical for seizure control: diazepam is used for acute seizure termination, while sodium valproate and levetiracetam are used for refractory seizures, often in combination for synergistic effects. In cases of refractory SE, propofol sedation may be required to suppress neuronal excitability. Adjunctive therapies include mannitol (a hyperosmotic agent that reduces intracranial pressure via osmotic diuresis), butylphthalide (which improves cerebral blood flow and microcirculation), and hydration therapy (which accelerates contrast excretion by increasing renal blood flow and urine output). Glucocorticoids are sometimes used empirically to inhibit inflammation and promote BBB repair; however, their efficacy in CIE is not supported by high-level clinical evidence, and no consensus exists regarding optimal dose, duration, or agent type. Corticosteroids were not used in our case, as the patient demonstrated rapid clinical improvement with antiepileptic and supportive therapy, with no evidence of severe BBB disruption. A recent case report by Pašara et al. 29 described a heart transplant patient with cardiac allograft vasculopathy who developed CIE following coronary angiography, presenting with seizures that were responsive to intravenous levetiracetam. This case aligns with our findings regarding delayed seizure onset, efficacy of levetiracetam, and absence of initial imaging abnormalities, highlighting the diagnostic challenges of CIE and the need for clinical vigilance. This study has several limitations. First, as a single case report, the findings are subject to limited generalizability, and conclusions regarding CIE complicated by SE cannot be extrapolated to the broader population. Second, incomplete information regarding the patient’s pre-existing microvascular status represents a potential confounding factor that cannot be fully excluded. Third, cerebrospinal fluid analysis was not performed, which could have further supported the exclusion of infectious or inflammatory etiologies, although these were reasonably excluded based on clinical and laboratory findings. In addition, no postoperative MRI was performed, limiting the radiological evidence available for a definitive diagnosis. Fourth, “Not Reported (NR)” entries in the literature review introduced data gaps; although cases with NR in key variables were excluded, incomplete reporting may still have affected the comprehensiveness and internal validity of the analysis. Future multicenter, large-sample clinical studies and basic research are warranted to address these limitations and provide more robust evidence for the diagnosis and management of CIE. Conclusion Seizures, including refractory SE, are a clinically relevant manifestation of CIE and should be considered in the differential diagnosis of acute central nervous system dysfunction following intra-arterial contrast administration. CIE is a diagnosis of exclusion; in the presence of contrast-associated cerebral edema or enhancement, it should be strongly considered. Although seizures are less common than other manifestations of CIE, clinical vigilance is essential to ensure timely diagnosis and treatment, thereby preventing severe outcomes. This case report contributes to the growing body of literature on CIE, highlighting its clinical variability and the importance of individualized management. Acknowledgments The authors wish to express their sincere thanks to the patient and her family for their kind participation in this work. Author contributions: LJ: Writing and figure organization. ZZ and SW: EEG examination, surgical procedure, and review; MW: Writing, review and editing; GS: Supervision, review and editing. All authors declare no conflict of interest. Funding: This work was supported by grants from the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (WKJ-ZJ-2340), Zhejiang Province “Vanguard Geese Leading Plan” Project (2025C02151), and Zhejiang Clinovation Pride (CXTD202501002). ORCID iD: Ming Wang https://orcid.org/0000-0003-1071-4472 Data availability statement The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author. Ethics statement Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article. Generative AI statement The authors declare that no generative AI was used in the creation of the manuscript. References Associated Data Data Availability Statement The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.